Lithium as a disease-modifying drug for bipolar disorder

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Bipolar disorder is increasingly viewed as a chronic, progressive condition.
• Lithium, a classic treatment, is underutilized despite growing evidence of its efficacy.
• Mood episodes may accelerate bipolar disorder progression, necessitating disease-modifying interventions.

Purpose of the Study:

• To argue that lithium functions as a disease-modifying agent in bipolar disorder.
• To highlight lithium's unique effects on biological mechanisms implicated in bipolar disorder.
• To advocate for increased clinical use of lithium, particularly in early disease stages.

Main Methods:

• Review of clinical trial and cohort study evidence.
• Analysis of lithium's impact on DNA, cellular, brain, and systemic levels.
• Examination of surrogate markers associated with bipolar disorder.

Main Results:

• Lithium uniquely affects numerous biological mechanisms in bipolar disorder.
• Clinical evidence supports lithium's efficacy, potentially superior to other medications.
• Long-term patient outcomes are improved with lithium-based treatment regimens.

Conclusions:

• Lithium should be conceptualized as a disease-modifying drug for bipolar disorder.
• Increased clinical use of lithium, especially early, can improve patient trajectories.
• Re-framing lithium's role may enhance its application in managing bipolar disorder.